EPCAM and breast cancer: Although EpCAM is considered the gold standard biomarker for CTCs detection, we observed that levels of EpCAM were lower (within 20-fold of the microarray background or blood controls) in 10 of 70 (14%) of micro-dissected breast cancer biopsies; consequently, the use of this unique biomarker could result in false negative cases [26].